[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015010625A2 - Peptídeos - Google Patents

Peptídeos

Info

Publication number
BR112015010625A2
BR112015010625A2 BR112015010625A BR112015010625A BR112015010625A2 BR 112015010625 A2 BR112015010625 A2 BR 112015010625A2 BR 112015010625 A BR112015010625 A BR 112015010625A BR 112015010625 A BR112015010625 A BR 112015010625A BR 112015010625 A2 BR112015010625 A2 BR 112015010625A2
Authority
BR
Brazil
Prior art keywords
peptides
relates
present
hemophilia
prcltryyssfvnme
Prior art date
Application number
BR112015010625A
Other languages
English (en)
Other versions
BR112015010625B1 (pt
Inventor
Wraith David
Streeter Heather
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1220328.7A external-priority patent/GB201220328D0/en
Priority claimed from GBGB1316660.8A external-priority patent/GB201316660D0/en
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of BR112015010625A2 publication Critical patent/BR112015010625A2/pt
Publication of BR112015010625B1 publication Critical patent/BR112015010625B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEPTÍDEOS. A presente invenção se refere a peptídeos parcialmente deriváveis do FVIII que são capazes de se ligar a uma molécula MHC de classe II sem processamento adicional de antígeno e serem reconhecidos por um fator VIII específicos de células T. Em particular, a presente invenção se refere a peptídeos que compreendem a sequência DNIMVTFRNQASRPY ou PRCLTRYYSSFVNME com modificações na extremidade N e C-terminais. A presente invenção também se relaciona com a utilização de tal peptídeo para a prevenção ou supressão de formação de anticorpo inibidor na hemofilia A e / ou hemofilia adquirida.
BR112015010625-0A 2012-11-12 2013-11-11 Peptídeos BR112015010625B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1220328.7 2012-11-12
GBGB1220328.7A GB201220328D0 (en) 2012-11-12 2012-11-12 Peptides
GBGB1316660.8A GB201316660D0 (en) 2013-09-19 2013-09-19 Peptides
GB1316660.8 2013-09-19
PCT/IB2013/060060 WO2014072958A1 (en) 2012-11-12 2013-11-11 Peptides

Publications (2)

Publication Number Publication Date
BR112015010625A2 true BR112015010625A2 (pt) 2017-08-22
BR112015010625B1 BR112015010625B1 (pt) 2023-03-07

Family

ID=49627013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010625-0A BR112015010625B1 (pt) 2012-11-12 2013-11-11 Peptídeos

Country Status (28)

Country Link
US (2) US20150306192A1 (pt)
EP (1) EP2917232B1 (pt)
JP (1) JP6247696B2 (pt)
KR (1) KR102165486B1 (pt)
CN (1) CN104903347B (pt)
AU (1) AU2013343024B2 (pt)
BR (1) BR112015010625B1 (pt)
CA (1) CA2890835C (pt)
CY (1) CY1119164T1 (pt)
DK (1) DK2917232T3 (pt)
EA (1) EA036483B1 (pt)
ES (1) ES2626881T3 (pt)
HR (1) HRP20170794T1 (pt)
HU (1) HUE033586T2 (pt)
IL (1) IL238627B (pt)
IN (1) IN2015DN03814A (pt)
LT (1) LT2917232T (pt)
MX (1) MX350777B (pt)
MY (1) MY176708A (pt)
NZ (1) NZ708812A (pt)
PH (1) PH12015501033B1 (pt)
PL (1) PL2917232T3 (pt)
PT (1) PT2917232T (pt)
RS (1) RS56069B1 (pt)
SG (1) SG11201503657UA (pt)
SI (1) SI2917232T1 (pt)
WO (1) WO2014072958A1 (pt)
ZA (1) ZA201503127B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565823B1 (en) 2017-01-04 2024-05-29 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-arrestin peptides and therapeutic uses thereof
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
IL301329A (en) 2020-09-23 2023-05-01 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1918298T3 (da) 2000-08-21 2010-11-29 Apitope Technology Bristol Ltd Peptid
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
FR2842812A1 (fr) * 2002-07-26 2004-01-30 Pf Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
JP2006188507A (ja) * 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
ES2386462T3 (es) * 2005-10-28 2012-08-21 Boehringer Ingelheim International Gmbh Ensayo de la actividad NS2/3 del virus de la hepatitis C
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2780761A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
KR102040867B1 (ko) * 2010-10-27 2019-11-07 박스알타 인코퍼레이티드 면역 관용 유도 및 면역진단을 위한 fviii 펩타이드

Also Published As

Publication number Publication date
AU2013343024A1 (en) 2015-05-21
PH12015501033A1 (en) 2015-07-27
NZ708812A (en) 2019-03-29
CY1119164T1 (el) 2018-02-14
ES2626881T3 (es) 2017-07-26
SI2917232T1 (sl) 2017-07-31
EP2917232A1 (en) 2015-09-16
US20210346476A1 (en) 2021-11-11
IN2015DN03814A (pt) 2015-10-02
EA036483B1 (ru) 2020-11-16
CA2890835C (en) 2021-11-23
PL2917232T3 (pl) 2017-09-29
BR112015010625B1 (pt) 2023-03-07
KR20150084852A (ko) 2015-07-22
HRP20170794T1 (hr) 2017-08-11
PT2917232T (pt) 2017-06-09
LT2917232T (lt) 2017-06-26
WO2014072958A1 (en) 2014-05-15
PH12015501033B1 (en) 2015-07-27
SG11201503657UA (en) 2015-06-29
JP6247696B2 (ja) 2017-12-13
CN104903347B (zh) 2020-02-21
CA2890835A1 (en) 2014-05-15
KR102165486B1 (ko) 2020-10-15
JP2016501182A (ja) 2016-01-18
EP2917232B1 (en) 2017-03-01
MX350777B (es) 2017-09-15
DK2917232T3 (en) 2017-06-12
US20150306192A1 (en) 2015-10-29
IL238627A0 (en) 2015-06-30
AU2013343024B2 (en) 2017-06-01
MX2015005973A (es) 2015-09-16
WO2014072958A8 (en) 2016-10-13
IL238627B (en) 2018-12-31
HK1209138A1 (en) 2016-03-24
ZA201503127B (en) 2016-10-26
MY176708A (en) 2020-08-19
RS56069B1 (sr) 2017-10-31
EA201590927A1 (ru) 2015-10-30
HUE033586T2 (hu) 2017-12-28
CN104903347A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
CY1121560T1 (el) Ανοσογονικη συνθεση
MX2017004559A (es) Receptores de celulas t.
NZ715038A (en) T cell receptors
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
BR112016012358A2 (pt) peptídios terapêuticos
UA118167C2 (uk) Пептид та його застосування
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
EA201490644A1 (ru) Терапевтические пептиды
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
IN2014DN10288A (pt)
BR112015010625A2 (pt) Peptídeos
BR112014026644A2 (pt) peptídeos de agonistas de par4
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
CO6460780A2 (es) Péptido
CA2863661C (en) Diagnostic peptides for lyme disease
WO2016016651A3 (en) Pfrh5 derived antigen for treatment of malaria
GB201118201D0 (en) Novel peptides
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
UA114015C2 (xx) Пептид

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2013, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD. (CN)